A 54-year-old male with biopsy proven Gleason 9 prostate cancer presented with rapidly increasing serum PSA level of 12.4 ng/ml and PSA doubling time <1 month after radical prostatectomy. Conventional imaging scans (chest, abdomen and pelvis CT and 99m Tc-MDP bone scintigraphy) were obtained which identified a imaging. While 18 F-FDG PET/CT was negative, 18 F-NaF PET/CT demonstrated numerous randomly distributed fluoride avid lesions in the skeleton (cervical/thoracic/lumbar spine, bilateral acetabuli pelvis, right clavicle) compatible with skeletal metastases (Fig. 2) . Follow-up MRI of the spine confirmed the bony lesions (see Fig. 1 ). Patient was then started on androgen deprivation therapy (bicalutamide/leuprolide acetate) and radiotherapy to a painful area in lower-thoracic spine (3250 cGy to T7-T11) after which his PSA declined to 0.6 ng/ml. Follow-up 18 F-NaF PET/CT showed increase in sclerosis on CT and decline in NaF uptake at sites of skeletal metastases. Conventional bone scintigraphy and CT are standard in the imaging evaluation of men with suspected metastatic disease based on rising serum PSA level. However, when available, 18 F-NaF PET/CT should be considered since it may be useful in early detection of occult skeletal metastases as clearly demonstrated here in our case. [1] [2] [3] 
